Statistical methods in hematology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Non-inferiority trial design
ANCOVA
Risk difference
All hematology trials
378 results
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES): Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES): primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement – (FIGHT-203): Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203): primary endpoint results, effect estimate with confidence…
- A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma: Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma: primary endpoint results,…
- A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma: Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma:…
- A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis: Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis: primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease: Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody: Complete Statistical AnalysisIndependent statistical analysis of A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody: primary…
- A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin’s Lymphomas, Solid Tumors and Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas,…
- A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia: Complete Statistical AnalysisIndependent statistical analysis of A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Trial In Patients With Advanced Cancer And Leukemia: Complete Statistical AnalysisIndependent statistical analysis of A Trial In Patients With Advanced Cancer And Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00878189).
- A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia: Complete Statistical AnalysisIndependent statistical analysis of A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate…
- A-TREATIndependent statistical analysis of American Trial Using Tranexamic Acid in Thrombocytopenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02578901).
- Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease: Complete Statistical AnalysisIndependent statistical analysis of Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN: Complete Statistical AnalysisIndependent statistical analysis of ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04639024).
- Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- ADMIRALIndependent statistical analysis of ADMIRAL (NCT04566055), evaluating AlloSure monitoring insights of renal allografts with longitudinal surveillance in kidney transplant rejection.
- Aflibercept for Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Aflibercept for Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00437034).
- AGILEComplete statistical analysis of the randomized phase 3 AGILE trial of AG-120 (ivosidenib) plus azacitidine versus placebo plus azacitidine in previously untreated acute myeloid leukemia with an IDH1 mutation.
- ALCYONEIndependent statistical analysis of ALCYONE (NCT05218603), evaluating daratumumab and bortezomib maintenance after induction therapy in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation.
- Alemtuzumab + Rituximab Consolidation in CLL: Complete Statistical AnalysisIndependent statistical analysis of Alemtuzumab + Rituximab Consolidation in CLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00771602).
- Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01361711).
- ALFA-0701Independent statistical analysis of the randomized phase 3 ALFA-0701 trial evaluating gemtuzumab ozogamicin with conventional chemotherapy in untreated acute myeloid leukemia.
- Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs: Complete Statistical AnalysisIndependent statistical analysis of Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs: primary endpoint results, effect estimate with confidence interval, sample-size…
- Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3): Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Allogeneic Stem Cell Transplant for CLL: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Stem Cell Transplant for CLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01629511).
- AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders: Complete Statistical AnalysisIndependent statistical analysis of AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia: primary endpoint results, effect estimate…
- An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma: primary endpoint results, effect estimate with…
- An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia: Complete Statistical AnalysisIndependent statistical analysis of An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size…
- An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant: Complete Statistical AnalysisIndependent statistical analysis of An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Anti-Tac(90 Y-HAT) to Treat Hodgkin’s Disease, Non-Hodgkin’s Lymphoma and Lymphoid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Arm Circumference Measurement With or Without Bioimpedance Spectroscopy in Finding Lymphedema Early in Patients With Stage I-III Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Arm Circumference Measurement With or Without Bioimpedance Spectroscopy in Finding Lymphedema Early in Patients With Stage I-III Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ASCEND-PIndependent statistical analysis of Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- AUGMENTIndependent statistical analysis of the phase 3 AUGMENT trial of rituximab plus lenalidomide versus rituximab plus placebo in relapsed or refractory indolent non-Hodgkin's lymphoma, including progression-free survival, overall survival, response endpoints, statistical…
- Autologous and Allogeneic Transplant for Relapsed Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Autologous and Allogeneic Transplant for Relapsed Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00802113).
- Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin’s Lymphoma (BMT CTN 0202): Complete Statistical AnalysisIndependent statistical analysis of Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure: Complete Statistical AnalysisIndependent statistical analysis of Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: primary endpoint…
- Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04676360).